{"id":"folr1","name":"Folate receptor alpha","symbol":"FOLR1","route":"/targets/folr1/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3791","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110195","uniprot":"https://www.uniprot.org/uniprotkb/P15328/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P15328","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2121","open-targets":"https://platform.opentargets.org/target/ENSG00000110195","civic":"https://civicdb.org/genes/2348/summary","oncokb":"https://www.oncokb.org/gene/FOLR1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOLR1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=FOLR1","depmap":"https://depmap.org/portal/gene/FOLR1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000110195-FOLR1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2348","omim":"https://www.omim.org/entry/136430"}],"products":[{"id":"chiauranib","name":"Chiauranib","status":"phase-3","modality":"small molecule","route":"/drugs/chiauranib/"},{"id":"farletuzumab-exatecan","name":"Farletuzumab-exatecan","status":"phase-2","modality":"ADC","route":"/drugs/farletuzumab-exatecan/"},{"id":"luveltamab-tazevibulin","name":"Luveltamab tazevibulin","status":"phase-3","modality":"ADC","route":"/drugs/luveltamab-tazevibulin/"},{"id":"mirvetuximab-soravtansine","name":"Mirvetuximab soravtansine","status":"approved","modality":"ADC","route":"/drugs/mirvetuximab-soravtansine/"},{"id":"pafolacianine","name":"Pafolacianine","status":"approved","modality":"Folate receptor-targeted near-infrared fluorescent imaging agent","route":"/drugs/pafolacianine/"},{"id":"rinatabart-sesutecan","name":"Rinatabart sesutecan","status":"phase-3","modality":"ADC","route":"/drugs/rinatabart-sesutecan/"},{"id":"sofetabart-mipitecan","name":"Sofetabart Mipitecan","status":"phase-3","modality":"ADC","route":"/drugs/sofetabart-mipitecan/"}],"trials":[{"id":"mirasol","name":"MIRASOL / GOG-3045","nct":"NCT04209855","phase":"3","status":"positive"},{"id":"soraya","name":"SORAYA","nct":"NCT04296890","phase":"3","status":"positive"},{"id":"nct07213804","name":"A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer","nct":"NCT07213804","phase":"3","status":"recruiting"},{"id":"nct07604766","name":"An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can","nct":"NCT07604766","phase":"3","status":"recruiting"},{"id":"nct04921527","name":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer","nct":"NCT04921527","phase":"3","status":"recruiting"},{"id":"nct04241315","name":"ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting","nct":"NCT04241315","phase":"3","status":"completed"},{"id":"nct07166094","name":"Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer","nct":"NCT07166094","phase":"3","status":"recruiting"},{"id":"nct07225270","name":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re","nct":"NCT07225270","phase":"3","status":"recruiting"},{"id":"nct07564141","name":"Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or","nct":"NCT07564141","phase":"3","status":"recruiting"},{"id":"nct06619236","name":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","nct":"NCT06619236","phase":"3","status":"active"},{"id":"nct05870748","name":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","nct":"NCT05870748","phase":"2/3"},{"id":"nct07714668","name":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","nct":"NCT07714668","phase":"2","status":"recruiting"},{"id":"nct06365853","name":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit","nct":"NCT06365853","phase":"2","status":"active"},{"id":"nct06682988","name":"A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar","nct":"NCT06682988","phase":"2","status":"recruiting"},{"id":"nct07059845","name":"A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult","nct":"NCT07059845","phase":"2","status":"recruiting"},{"id":"nct06890338","name":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo","nct":"NCT06890338","phase":"2","status":"recruiting"},{"id":"nct06434909","name":"CYTALUX™for the Intraoperative Imaging of Prostate Cancer","nct":"NCT06434909","phase":"2","status":"completed"},{"id":"nct04274426","name":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","nct":"NCT04274426","phase":"2","status":"active"},{"id":"nct05456685","name":"Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov","nct":"NCT05456685","phase":"2","status":"active"},{"id":"nct07825753","name":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","nct":"NCT07825753","phase":"2","status":"planned"},{"id":"nct07039526","name":"Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer","nct":"NCT07039526","phase":"2","status":"recruiting"},{"id":"nct07288177","name":"Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer","nct":"NCT07288177","phase":"2","status":"recruiting"},{"id":"nct06390995","name":"A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors","nct":"NCT06390995","phase":"1/2","status":"active"},{"id":"rainfol-01","name":"RAINFOL-01 (Rina-S)","nct":"NCT05579366","phase":"1/2","status":"active"},{"id":"nct07744763","name":"A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors","nct":"NCT07744763","phase":"1/2","status":"recruiting"},{"id":"nct07480954","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","nct":"NCT07480954","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["abbvie","chipscreen","cspc","eli-lilly","genmab","on-target-laboratories","profoundbio","sutro-biopharma"],"keyPapers":[],"hotspots":[],"openQuestions":[{"id":"folr1-threshold","question":"Can folate-receptor-alpha ADCs work below the 75% high-expression cut-off used for mirvetuximab, and in platinum-sensitive disease?","stage":"clinical","actor":"industry","source":{"label":"MIRASOL (ClinicalTrials.gov)","url":"https://clinicaltrials.gov/study/NCT04209855"}}],"assays":[{"id":"folr1-ventana","name":"VENTANA FOLR1 (FOLR1-2.1) RxDx Assay","cutoff":"At least 75% of viable tumour cells with membrane staining of at least 2+ intensity (mirvetuximab soravtansine, ovarian cancer)"}],"resistance":[{"class":"parp-inhibitor","mechanism":"BRCA1/2 reversion mutations","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}